Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma

被引：0
|
作者：
Risa Motai
Michi Sawabe
Shigenori Kadowaki
Eiichi Sasaki
Daisuke Nishikawa
Hidenori Suzuki
Shintaro Beppu
Hoshino Terada
Nobuhiro Hanai
机构：
[1] Aichi Cancer Center,Department of Head and Neck Surgery
[2] Aichi Cancer Center,Department of Medical Oncology
[3] Aichi Cancer Center,Department of Pathology and Molecular Diagnostics
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Head and neck cancer; EXTREME; Paclitaxel; Cetuximab; Platinum-refractory; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1188 / 1195
页数：7
相关论文
共 50 条
  • [1] Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma
    Motai, Risa
    Sawabe, Michi
    Kadowaki, Shigenori
    Sasaki, Eiichi
    Nishikawa, Daisuke
    Suzuki, Hidenori
    Beppu, Shintaro
    Terada, Hoshino
    Hanai, Nobuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1188 - 1195
  • [2] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [3] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [4] Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
    Taira, Shinichiro
    Nakano, Kenji
    Tomomatsu, Junichi
    Marshall, Shouko
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] A comparison of cetuximab-containing regimens for recurrent/metastatic squamous cell head and neck carcinoma: the clinical significance of weekly paclitaxel and cetuximab
    Nakano, K.
    Marshall, S.
    Taira, S.
    Sato, Y.
    Tomomatsu, J.
    Sasaki, T.
    Shimbashi, W.
    Fukushima, H.
    Yonekawa, H.
    Mitani, H.
    Kawabata, K.
    Takahashi, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
    Roy, C. Le
    Vernerey, D.
    Evin, C.
    Richard, S.
    Crespel, C.
    Samaille, T.
    Tourneau, C. Le
    Huguet, F.
    CLINICAL ONCOLOGY, 2022, 34 (12) : E473 - E481
  • [7] Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution
    Diaz de Corcuera, I.
    Serrano, C.
    Perez, J.
    Quispe, I.
    Arguis, M.
    Munoz, E.
    Benavente, S.
    Martinez, P.
    Parera, M.
    del Campo, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME
    Chevalier, Thomas
    Daste, Amaury
    Saada-Bouzid, Esmaa
    Loundou, Anderson
    Peyraud, Florent
    Lambert, Tiphaine
    Le Tourneau, Christophe
    Peyrade, Frederic
    Dupuis, Charlotte
    Alfonsi, Marc
    Fayette, Jerome
    Reure, Juliette
    Huguet, Florence
    Fakhry, Nicolas
    Toullec, Clemence
    Salas, Sebastien
    CANCER MEDICINE, 2021, 10 (12): : 3952 - 3963
  • [9] Impact of EXTREME regimen and cetuximab, cisplatin, and paclitaxel-based regimen on clinical and humanistic outcomes in patients suffering from recurrent or metastatic head and neck squamous cell cancer
    Khadela, A. D.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
  • [10] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
12345